News Sentiment

NAMS sentiment intelligence

NewAmsterdam Pharma Company N.V. Ordinary Shares news scored across direct company coverage, industry context, sector read-through, source quality, and freshness.

Chart Weekly report Factors RSS feed
Weighted score 55 Balanced news tone 54 relevant articles
Exchange NASDAQ United States
Sector Healthcare Market context
Industry Biotechnology Read-through group
Latest close 31.68 Week of 17 Jul 2026
Weighted tone 55/100

Balanced news tone

Market reaction Price moving ahead of tone

Price is moving more forcefully than the current news tone suggests.

Primary event Market update

76/100 classification confidence.

Company focus 46

directly relevant articles

Source quality 1

high-authority source matches

Trend context Trend inactive

-10.2% over one week, +6.2% over four weeks, trend inactive, and materially above fair value.

Latest direct headline Positive

NewAmsterdam Pharma publishes obicetrapib Alzheimer’s prevention research presentation

Market Reaction

Price moving ahead of tone

63/100 confidence

Price is moving more forcefully than the current news tone suggests.

Primary event Market update 76/100 classification
One-week reaction -10.2% Price reacting lower
Trend fit Trend inactive 6.2% over four weeks
Fair value 40.2% Materially above fair value

Sentiment Mix

Positive, neutral, negative

Weighted by relevance
Positive 13
Neutral 38
Negative 3

Relevance

Why the article matched

Direct first
Direct company coverage 46
Industry context 8
Sector context 0

Sources

Coverage mix

Publishers
TradingView 16
Market source 15
Stock Titan 4
simplywall.st 4
Finviz 2
GlobeNewswire 2
MT Newswires 2
Bitget 1

Event Lens

What the news is about

Classified themes
Earnings 26
Market update 24
Regulatory and legal 2
Analyst action 2

Sentiment Trail

Score over time

50 baseline
Above 50 Neutral zone Below 50

News Tape

Relevant headlines

Showing 1-30 of 54
Bitget Direct company coverage

NewAmsterdam Pharma publishes obicetrapib Alzheimer’s prevention research presentation

NewAmsterdam Pharma has released a research presentation on the use of its CETP inhibitor, obicetrapib, for Alzheimer's prevention. A Phase 3 substudy showed that obicetrapib reduced plasma p-tau217 after 12 months, particularly in APOE4/E4 carriers, and positively impacted other

Tone
Positive 71/100
Event
Market update
Published
17 Jul 2026 09:10
Source
Bitget
TradingView Direct company coverage

Enterprise value to revenue forward of NewAmsterdam Pharma Company N.V. – MUN:KH6

This article provides an analysis of the enterprise value to revenue forward for NewAmsterdam Pharma Company N.V. (MUN:KH6). It highlights financial data and market specifics for the company, listed on the Munich Stock Exchange. The information is presented within a financial dat

Tone
Neutral 50/100
Event
Earnings
Published
14 Jul 2026 05:11
Source
TradingView
Stock Traders Daily Direct company coverage

Price-Driven Insight from (NAMSW) for Rule-Based Strategy

This article provides a price-driven insight for Newamsterdam Pharma Company N.v. Warrant (NASDAQ: NAMSW), detailing AI-generated trading strategies for different risk profiles. It highlights institutional trading strategies, multi-timeframe signal analysis, and real-time trading

Tone
Neutral 50/100
Event
Market update
Published
14 Jul 2026 03:11
Source
Stock Traders Daily
TradingView Direct company coverage

Price to sales forward of NewAmsterdam Pharma Company N.V. – NASDAQ:NAMS

This article provides financial information for NewAmsterdam Pharma Company N.V. (NASDAQ: NAMS), specifically focusing on its forward price-to-sales ratio. It presents various financial data points and market information for the company, accessible through TradingView. The conten

Tone
Neutral 50/100
Event
Market update
Published
12 Jul 2026 08:39
Source
TradingView
Quartr Direct company coverage

NewAmsterdam Pharma Company (NAMS) Study Update Summary

NewAmsterdam Pharma Company (NAMS) provided an update on its BROOKLYN Phase III trial for obicetrapib, an investigational drug for Heterozygous familial hypercholesterolemia (HeFH). The study demonstrated that obicetrapib significantly reduced LDL-C by 36.3% at 84 days and 41.5%

Tone
Positive 90/100
Event
Regulatory and legal
Published
10 Jul 2026 21:10
Source
Quartr
Sahm Direct company coverage

NewAmsterdam Pharma (NAMS) Alzheimer’s Data Push Puts Fair Value Back In Focus

NewAmsterdam Pharma (NAMS) is gaining attention due to its upcoming presentation of new obicetrapib data at the Alzheimer’s Association International Conference, highlighting its potential in early Alzheimer's disease prevention. Despite trading at a premium on a price-to-book ba

Tone
Positive 65/100
Event
Market update
Published
06 Jul 2026 06:39
Source
Sahm
Finviz Direct company coverage

NAMS - NewAmsterdam Pharma Company NV Latest SEC Filings

This article provides the latest SEC filings information for NewAmsterdam Pharma Company NV (NAMS), including its last closing price, various financial metrics, stock performance data, and institutional/insider ownership details. It presents a comprehensive overview of the compan

Tone
Neutral 50/100
Event
Market update
Published
03 Jul 2026 17:09
Source
Finviz
Market source Direct company coverage

NewAmsterdam Pharma Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

NewAmsterdam Pharma N.V. announced inducement grants of share options and restricted stock units to four new non-executive hires under Nasdaq Listing Rule 5635(c)(4). The grants, made on July 1, 2026, include 28,700 ordinary shares for options with an exercise price of $35.17 and

Tone
Neutral 50/100
Event
Market update
Published
03 Jul 2026 04:40
Source
Market source
Finviz Direct company coverage

NAMS - NewAmsterdam Pharma Company NV Options

This article provides detailed financial data and performance metrics for NewAmsterdam Pharma Company NV (NAMS). It includes information on its last closing price, stock performance over various periods, key financial ratios, insider and institutional ownership, and analyst recom

Tone
Neutral 50/100
Event
Analyst action
Published
02 Jul 2026 21:39
Source
Finviz
Stock Titan Direct company coverage

NewAmsterdam Pharma awards stock incentives to four new hires

NewAmsterdam Pharma has granted equity awards to four new non-executive hires under its 2024 Inducement Plan, in accordance with Nasdaq Listing Rule 5635(c)(4). The awards consist of share options for 28,700 ordinary shares with an exercise price of $35.17 and 8,100 restricted st

Tone
Positive 61/100
Event
Market update
Published
02 Jul 2026 20:10
Source
Stock Titan
Yahoo! Finance Canada Direct company coverage

NewAmsterdam Pharma Announces Upcoming Presentations at the Alzheimer's Association International Conference (AAIC) 2026

NewAmsterdam Pharma N.V. announced it will present data on its drug obicetrapib as a potential therapy for early Alzheimer's disease at the Alzheimer's Association International Conference (AAIC) 2026. The presentations will highlight insights from the BROADWAY trial regarding pr

Tone
Positive 71/100
Event
Market update
Published
02 Jul 2026 05:09
Source
Yahoo! Finance Canada
Stock Titan Direct company coverage

NewAmsterdam Pharma puts obicetrapib in Alzheimer’s spotlight at AAIC 2026

NewAmsterdam Pharma will present multiple obicetrapib data sets related to Alzheimer's prevention at the Alzheimer's Association International Conference (AAIC) 2026 in London. The presentations will cover predictors of P-tau217, undiagnosed Alzheimer’s pathology in cardiovascula

Tone
Positive 71/100
Event
Market update
Published
01 Jul 2026 11:39
Source
Stock Titan
GlobeNewswire Direct company coverage

NewAmsterdam Pharma Announces Upcoming Presentations at the

NewAmsterdam Pharma N.V. will present data on its investigational drug obicetrapib for the prevention of early Alzheimer's disease at the Alzheimer's Association International Conference (AAIC) 2026. The presentations will highlight insights from the BROADWAY trial regarding P-ta

Tone
Positive 71/100
Event
Regulatory and legal
Published
01 Jul 2026 11:39
Source
GlobeNewswire
TradingView Direct company coverage

NewAmsterdam Pharma Company N.V.

This page provides access to NewAmsterdam Pharma Company N.V.'s SEC filings and other corporate documents, including earnings reports and event transcripts from various healthcare conferences. It details the company's financial performance, clinical trial advancements for Obicetr

Tone
Neutral 50/100
Event
Earnings
Published
01 Jul 2026 10:39
Source
TradingView
TradingView Direct company coverage

Price to sales forward of NewAmsterdam Pharma Company N.V. – BOATS:NAMSW

This article provides financial information for NewAmsterdam Pharma Company N.V. (NAMSW), specifically highlighting its price to sales forward metric. It also notes that the market for NAMSW is currently closed with no trades. The content is hosted on TradingView, which offers va

Tone
Neutral 50/100
Event
Market update
Published
29 Jun 2026 00:39
Source
TradingView
TradingView Direct company coverage

Price to book forward of NewAmsterdam Pharma Company N.V. – NASDAQ:NAMS

This article provides the "Price to book forward" for NewAmsterdam Pharma Company N.V., traded under the NASDAQ symbol NAMS. It appears to be a financial data point from a market overview section, typical for platforms like TradingView. The content is concise, focusing solely on

Tone
Neutral 50/100
Event
Market update
Published
28 Jun 2026 15:10
Source
TradingView
TradingView Direct company coverage

Enterprise value to revenue forward of NewAmsterdam Pharma Company N.V. – NASDAQ:NAMSW

This article provides the enterprise value to revenue forward for NewAmsterdam Pharma Company N.V. (NASDAQ: NAMSW). The data presented shows the value, change, and percentage change for this financial metric. The information is sourced from TradingView, with market data from ICE

Tone
Neutral 50/100
Event
Earnings
Published
28 Jun 2026 09:11
Source
TradingView
TradingView Direct company coverage

Enterprise value to revenue forward of NewAmsterdam Pharma Company N.V. – BOATS:NAMSW

The article focuses on the enterprise value to revenue forward of NewAmsterdam Pharma Company N.V. (NAMSW) as listed on the Blue Ocean Alternative Trade System. It provides a financial overview and market information for the company, indicating that the market is currently closed

Tone
Neutral 50/100
Event
Earnings
Published
28 Jun 2026 07:11
Source
TradingView
TradingView Direct company coverage

Price to book forward of NewAmsterdam Pharma Company N.V. – LSX:A3DUAC

This article provides the "Price to book forward" for NewAmsterdam Pharma Company N.V. (LSX:A3DUAC) on the Lang & Schwarz Exchange. The content highlights financial data and indicates that the market was closed with no trades. It also includes general disclaimers about data provi

Tone
Neutral 50/100
Event
Market update
Published
28 Jun 2026 03:09
Source
TradingView
TradingView Direct company coverage

Enterprise value to EBITDA forward of NewAmsterdam Pharma Company N.V. – NASDAQ:NAMSW

This article provides the enterprise value to EBITDA forward for NewAmsterdam Pharma Company N.V. (NASDAQ: NAMSW). It presents this financial metric for the company, indicating its market valuation relative to its earnings before interest, taxes, depreciation, and amortization. T

Tone
Neutral 50/100
Event
Earnings
Published
28 Jun 2026 00:10
Source
TradingView
TradingView Direct company coverage

NewAmsterdam Pharma Company N.V. Actuals & Estimates (MUN:KH6)

NewAmsterdam Pharma Company N.V. (KH6) financial actuals and estimates are detailed, including income statement, balance sheet, and cash flow data, as well as analyst forecasts. The article provides key financial metrics such as earnings per share, revenue, and EBITDA, and states

Tone
Neutral 50/100
Event
Earnings
Published
27 Jun 2026 14:41
Source
TradingView
TradingView Direct company coverage

NAMS Forecast — Price Target — Prediction for 2027

NewAmsterdam Pharma Company N.V. (NAMS) stock is currently trading at $33.24, with analysts predicting a future price range between $38.00 and $60.00. The company's stock has seen an 82.04% increase over the last year, and it is expected to release its next earnings report on Aug

Tone
Positive 70/100
Event
Earnings
Published
27 Jun 2026 14:11
Source
TradingView
TradingView Direct company coverage

NewAmsterdam Pharma Company N.V. Actuals & Estimates (NASDAQ:NAMS)

This article provides an overview of NewAmsterdam Pharma Company N.V. (NASDAQ: NAMS) including its current stock price, historical performance, financial estimates, and analyst forecasts. It details financial actuals for revenue and earnings, future earnings dates, and general co

Tone
Positive 66/100
Event
Earnings
Published
27 Jun 2026 07:39
Source
TradingView
TradingView Direct company coverage

NewAmsterdam Pharma Company N.V. Actuals & Estimates (HAM:KH6)

This article provides an overview of NewAmsterdam Pharma Company N.V. (HAM:KH6) including its financial actuals and estimates, as well as analyst forecasts. It covers key financial data such as earnings, revenue, net income, and EBITDA, along with historical stock prices and futu

Tone
Neutral 50/100
Event
Earnings
Published
26 Jun 2026 12:10
Source
TradingView